

To: 5.1.2e [5.1.2e @rivm.nl]
From: 5.1.2e @editorialmanager.com
Sent: Sat 9/5/2020 10:02:48 AM
Subject: Invitation to review for Journal of Pharmaceutical Analysis
Received: Sat 9/5/2020 10:02:44 AM

Manuscript Number: JPA_2020_321

The review of SARS-CoV2: Recent perspective and advances in pathogenesis, treatment and detection

5.1.2e

Dear 5.1.2e

I would like to invite you to review the above referenced manuscript submitted by 5.1.2e, as I believe it falls within your expertise and interest. The abstract for this manuscript is included below.

You should treat this invitation, the manuscript and your review as confidential. You must not share your review or information about the review process with anyone without the agreement of the editors and authors involved, even after publication. This also applies to other reviewers' "comments to author" which are shared with you on decision (and vice versa).

Please respond to this invitation at your earliest opportunity.

If you would like to review this paper, please click this link:
<https://www.editorialmanager.com/jpa/l.asp?i=23493&l=RACYEW5H>

If you have a conflict of interest or do not wish to review this paper, please click this link:
<https://www.editorialmanager.com/jpa/l.asp?i=23494&l=ZJFLPAPZ>

If you decline to review I would appreciate your suggestions for alternate reviewers.

If, for any reason, the above links do not work, please log in as a reviewer at <https://www.editorialmanager.com/jpa/>

Since timely reviews are of utmost importance to authors, I would appreciate receiving your review within 21 days of accepting this invitation.

Once you submitted your review, you will receive a notification from Elsevier's reviewer recognition platform, which provides you with a link to your "My Elsevier Reviews" private profile page. You can collect your review certificates, editor recognition as well as discounts for Elsevier services from your profile page

I hope you will be able to review this manuscript.
Thank you in advance for your contribution and time.

Kind regards,

5.1.2e

Journal of Pharmaceutical Analysis

Please also note that authors have been invited to convert their supplementary material into a Data in Brief article (a data description article). You may notice this change alongside the revised manuscript. You do not need to review this but may need to look at the files in order to confirm that any supporting information you requested is present there.

Please also note that authors have been invited to convert methods-related supplementary material into a MethodsX article (a detailed description of their methods). You may notice this change alongside the revised manuscript. You do not need to review this but may need to look at the files in order to confirm that any supporting information you requested is present there.

Abstract:

The outbreak of novel Coronavirus (2019-nCoV) which began in Wuhan, China, has rapidly spread in many countries and and it's currently considered a pandemic. The virus (SARS-CoV-2) caused severe acute respiratory syndrome and related to SARS-CoV and MERS-CoV. In this review, we provide an introduction of the general features of SARS-CoV-2, its pathogenesis, the existing knowledge on immunological properties, transmission routs, diagnostic features and especially discussed about new approaches for treatment and

prevention, different methods including Nucleic acid base assays, serological testing and MALDITOF-MS and LC-MS technology for detection which may be useful to provide new insights for advancing and improving detection primers, probes, methods/techniques and potential targets for drug designation and therapeutic candidate against the virus.

More information and support

FAQ: How do I respond to an invitation to review in Editorial Manager?
https://service.elsevier.com/app/answers/detail/a_id/28524/supporthub/publishing/

You will find guidance and support on reviewing, as well as information including details of how Elsevier recognizes reviewers, on Elsevier's Reviewer Hub: <https://www.elsevier.com/reviewers>

FAQ: How can I reset a forgotten password?
https://service.elsevier.com/app/answers/detail/a_id/28452/supporthub/publishing/
For further assistance, please visit our customer service site: <https://service.elsevier.com/app/home/supporthub/publishing/>
Here you can search for solutions on a range of topics, find answers to frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/7 to our customer support team by phone and 24/7 by live chat and email

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. (Use the following URL: <https://www.editorialmanager.com/jpa/login.asp?a=r>). Please contact the publication office if you have any questions.